We have launched our new telemedicine/telehealth (virtual) program using the newest-FDA approved weight loss medication (semaglutide) or Mounjaro. Semaglutide (as Wegovy) was approved June 4, 2021 for weight loss and long term weight management. As of August 17, 2022, there continues to be a national shortage of Wegovy and Ozempic. Ozempic is injectable semaglutide that was approved in 2017 for diabetes. Mounjaro (tirazepatide) was approved in May 2022 for diabetes and is in clinical studies to get approval for weight loss and long term weight management.
As an alternative to Wegovy/Ozempic, we prescribe compounded semaglutide or Mounjaro (tirzepatide). These are available by prescription only and one tool of a physician-supervised weight management program that includes diet, exercise, and behavior modification.
Dr. Garza has struggled with her weight for 25 years. While being an advocate and expert for existing prescription weight loss medications, she most recently she has lost over 40 lbs with compounded semaglutide.
Our new online program does not accept insurance. Please contact us at email@example.com or call us at 214-771-9898 for more information about our telemedicine program using weekly injectables. If you are interested in seeing Dr. Garza or Melissa Pham, FNP-C in our Plano office for comprehensive weight loss options, please contact us at (972) 303-8955.